Trial · NCT07089888
Registered outcomes17
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 17 of 17
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage of Participants with an sUA Level <5.0 mg/dL at Week 24 | Week 24 | |
| Secondary | Percentage of Participants who Experience Complete Response (CR) or Partial Response (PR) of ≥1 Target Tophus at Week 76 | Week 76 | |
| Secondary | Percentage of Participants who Experience CR of ≥1 Target Tophus at Week 76 | Week 76 | |
| Secondary | Percentage of Participants with an sUA Level <4.0 mg/dL at Week 24 | Week 24 | |
| Secondary | Mean Rate of Gout Flares Requiring Treatment from Week 36 Through Week 76 | Week 36 through Week 76 | |
| Secondary | Percentage of Participants with an sUA Level <5.0 mg/dL at Week 24 and No Gout Flares Requiring Treatment from Week 36 Through Week 76 | Week 24 and Week 36 through Week 76 | |
| Secondary | Mean Change from Baseline in sUA at Week 24 | Baseline and Week 24 | |
| Secondary | Mean Percent Change from Baseline in the Sum of the Areas for all Target Tophi at Each Visit | Baseline to Week 80 | |
| Secondary | Percentage of Participants who Do Not have a Gout Flare Requiring Treatment from Week 36 through Week 76 | Week 36 through Week 76 | |
| Secondary | Percentage of Participants with an sUA Level <5.0 mg/dL at Each Visit | Up to Week 80 | |
| Secondary | Percentage of Participants with an sUA Level <4.0 mg/dL at Each Visit | Up to Week 80 | |
| Secondary | Percentage of Participants with an sUA Level <3.0 mg/dL at Each Visit | Up to Week 80 | |
| Secondary | Absolute Change from Baseline in sUA Levels at Each Visit | Baseline to Week 80 | |
| Secondary | Percent Change from Baseline in sUA Levels at Each Visit | Baseline to Week 80 | |
| Secondary | Percentage of Participants with a Gout Flare Requiring Treatment at Each Month Between Week 24 and the End of Study | Week 24 to Week 80 | |
| Secondary | Percentage of Participants with Treatment-emergent Adverse Events (TEAEs) | Up to Week 80 | |
| Secondary | Percentage of Participants with Serious Adverse Events (SAEs) | Up to Week 80 |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07089888/registered